Skip to main content

Back to Topics



Reishi Mushroom and Cancer

August 2, 2022

General Information: A quick Google search of “ Reishi Mushroom and cancer” returns multiple headlines about its health benefits, including that it “fights cancer.”

Known as the mushroom of immortality, Ganoderma lucidum contains polysaccharides and a class of compounds called triterpenes. In vitro studies have demonstrated that these compounds derived from the Reishi mushroom have cytotoxic effects on cancer cells.

Proposed Mechanisms of Action

In vitro studies suggest that triterpenes and polysaccharides of the Reishi mushroom affect cell signaling in cancer cells. Several studies demonstrate that extracts of Reishi mushrooms downregulate VEGF1,2 and MAPK signaling,3,4 as well as induce cell cycle arrest, apoptosis, and/or autophagy.5-12

Evidence in Favor of Anticancer Activity

A Cochrane systematic review and meta-analysis included 5 randomized controlled trials that evaluated G. lucidum medications with placebo or an active comparator in patients with cancer.13 Patients taking G. lucidum experienced improved response to chemotherapy or radiotherapy (relative risk, 1.50; 95% CI, 0.90-2.51; P = .02), but there was no benefit when G. lucidum was used alone. G. lucidum intake increased the percentage of CD3, CD4, and CD8-positive cells, and increased the number of leukocytes, NK-cell activity, and the CD4/CD8 ratio. The review found minimal adverse effects, including nausea and insomnia, with no hematologic or hepatologic toxicities.

In a small, randomized controlled trial, 5 out of 40 patients with gynecologic cancer experienced stabilized disease as a result of salvage therapy with a water-based extract of G. lucidum and its spores.

An open-label study compared the effect of extracts from Agaricus blazei (Murill mushroom) with G. lucidum among 47 men who experience biochemical failure after radical treatment of prostate cancer.15 There was no effect of either mushroom extract on the primary endpoint of partial response rate (defined as at least a 50% decrease in serum prostate-specific antigen). Read more:

Follow Us